Progenics Pharmaceuticals, Inc.
http://www.progenics.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Progenics Pharmaceuticals, Inc.
BTIG Analyst Zooms Into Alcon’s Revamp Into ‘Building A Pharma Company Inside A Device Company’
In his recent report on Alcon, BTIG analyst Ryan Zimmerman estimated that its pharmaceutical portfolio could generate close to $900m in fiscal year 2022.
Finance Watch: Third Harmonic Attempts A Flight Through The IPO Window
Public Company Edition: Third Harmonic hopes to double its money, raising up to $150m. Also, Halozyme priced a $625m note sale to retire debt and repurchase shares, while Viridian raised $270m in an offering after positive early data, and Clarus cut jobs while Endo finalized a restructuring plan.
Alcon Buys Aerie, Reaffirming Commitment To Pharma Space
With the $770m acquisition, Alcon will gain two commercial eye drop products for glaucoma and a Phase III candidate for dry eye.
Ups And Downs In Protein Degraders: Big Deals For BMS, Merck KGaA, Safety Worries For Kymera
Kymera has seen its share price fall more than 30% this week as investors struggle to gauge how much future market potential targeted protein degraders will have.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
-
Diagnostic Imaging Equipment & Supplies
-
Digital Health
- Artificial Intelligence
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- ADMET
-
Large Molecule
- Other Names / Subsidiaries
-
- Molecular Insight Pharmaceuticals, Inc.
- PSMA Development Company
- UR Labs (URL)